The most consequential capital shift of the next decade is currently ongoing. $124 trillion is transferring between generations, with women receiving a disproportionate share. Those women are the same people who have lived inside one of the most persistent market inefficiencies in modern healthcare.

For the first time in history, the people with the capital, the lived experience, and the investment sophistication are the same people.

This keynote makes the case that the Great Wealth Transfer and the women's health investment opportunity are not two separate stories. Rather, they are the same convergence and examines what that means for private wealth, healthcare investing, and the institutions that recognise it first.

Designed for: private banks, family offices, wealth management conferences, healthcare investment forums.

The most significant investment opportunities of any era are rarely found where capital is already looking. They are found in the gap between what the data shows and what the consensus believes; in categories that are structurally overlooked, systematically misclassified, or simply outside the frameworks most investors use to evaluate opportunity.

This keynote examines how capital blind spots form, why they persist, and what it takes to identify them before they become consensus.

Women's health serves as the primary case study; a category with over $100 billion in exits over 25 years that is still routinely described as emerging.

Designed for: asset managers, institutional investors, investment committees, leadership forums focused on long-term capital strategy.

For decades, women's health has captured less than 6% of private healthcare investment despite representing half the global population. This is not a medical oversight. It is a market inefficiency and market inefficiencies, when they correct, can create extraordinary returns for the investors who saw them first.

This keynote makes the institutional investment case for women's health as an asset class.

Drawing on 25 years of private capital experience and proprietary research, it examines how structural assumptions in capital allocation created one of the most persistent mispricings in modern healthcare and why that mispricing is now beginning to correct.

Designed for: investment conferences, private banking forums, family office gatherings, healthcare investor events.

Scientific breakthroughs do not automatically become investable opportunities. The path from promising research to scalable business is shaped by capital decisions; who funds what, at which stage, with what time horizon and risk tolerance.

This keynote examines the structural relationship between capital markets and healthcare innovation and why certain categories receive sustained investment while others stall.

Women's health serves as a primary lens: a category where the science has long outpaced the capital, and where the gap is now closing at pace.

Designed for: healthcare investors, life sciences conferences, private equity forums, innovation leadership events.